Compare HubSpot Inc (HUBS) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Incyte Corporation — how do they compare? HubSpot Inc trades at $209.82 (market cap $11.00B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 2.2× HubSpot Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.
| HUBS | INCY | |
|---|---|---|
Market Cap | $11.00B | $24.54B |
Sector | Technology | Health |
52-Week High | $522.97 | $129.93 |
52-Week Low | $170.39 | $81.61 |
Enterprise Value | $9.89B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $210.12, down 2.68% amid a bearish technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates with $3.26 versus $3.02 expected, but lowered its 2026 customer-growth forecast, causing investor concern. Revenue growth remains robust at 20% year-over-year, while profitability metrics show improvement, with net income margin rising to 4.26% in 2025 from negative figures in prior years.
The outlook is mixed: analyst consensus is bullish with a $233.93 price target, but near-term risks include execution challenges in AI adoption and a securities fraud investigation. Long-term growth depends on successful AI product integration and customer acquisition recovery, though competitive and regulatory pressures persist.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
